A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells

André Franken, Mahdi Rivandi, Liwen Yang, Bernadette Jäger, Natalia Krawczyk, Ellen Honisch, Dieter Niederacher, Tanja Fehm † and Hans Neubauer *,†

Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Duesseldorf, 40225 Duesseldorf, Germany; andre.franken@med.uni-duesseldorf.de (A.F.); mahdi.rivandi@med.uni-duesseldorf.de (M.R.); liwen.yang@med.uni-duesseldorf.de (L.Y.); bernadette.jaeger@med.uni-duesseldorf.de (B.J.); natalia.krawczyk@med.uni-duesseldorf.de (N.K.); Ellen.Honisch@med.uni-duesseldorf.de (E.H.); niederac@med.uni-duesseldorf.de (D.N.); tanja.fehm@med.uni-duesseldorf.de (T.F.)

* Correspondence: hans.neubauer@med.uni-duesseldorf.de
† Both authors share last authorship.

Received: 9 April 2020; Accepted: 8 May 2020; Published: 13 May 2020

Abstract: Targeted therapy has become the preferred approach to treat most cancers, including metastatic breast cancer. Using liquid biopsies, which can act as a dynamic diagnostic tool, is an appealing concept to identify effective therapies. In order to identify mutations from circulating tumor cells (CTCs) on single cell level, we have developed a multiplex PCR-based next generation sequencing-panel. The CTCs were enriched using the CellSearch system and isolated by micromanipulation followed by whole genome amplification of their DNA. Afterwards, mutation hotspot regions in the PIK3CA, the ESR1, the AKT1, and the ERBB2 genes were amplified and barcoded. Sequencing was performed on a MiSeq system. The assay was validated with cells from various cell lines displaying the expected mutations. Mutations that provide the basis for potential targeted therapies were detected in 10 out of 13 patients in all analyzed genes. In four patients, mutations in more than one gene were observed—either in the same cell or in different cells, suggesting the presence of different tumor cell clones, which might be targeted with combination therapies. This assay is a time and cost effective tool to investigate the most relevant genomic positions indicative for targeted therapies in metastatic breast cancer. It can support therapy decision to improve the treatment of cancer patients.

Keywords: breast cancer; circulating tumor cells; liquid biopsy; metastatic breast cancer; panel sequencing; targeted therapy; single cell analysis

1. Introduction

In the last decades, targeted therapy has become the preferred approach to treat most cancers. However, obtaining information to choose a targeted therapy is challenging: biopsies of recurrent or metastatic lesions are invasive and cannot be performed when clinical conditions have worsened or when a tumor is inaccessible [1]. Furthermore, the genomic profile of biopsy tissues provides a picture limited to a single point in space and time, and may, thus, under-represent intratumoral heterogeneity [2]. The predictive utility of tissue biopsies is limited by such factors, worsened still by the continuous evolution of the tumor in response to endogenous and exogenous selective pressures [3]. Deriving information about the primary tumor or metastatic lesions from liquid biopsies, which may act as a dynamic diagnostic tool, is an appealing concept to overcome this challenge [4,5].
Potential biomarkers are circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). CTCs are shed into the blood by tumor tissue and are commonly considered as precursor cells for metastasis formation [6,7]. ctDNA as part of cell free DNA describes tumorous DNA circulating in the blood, which has been released from degraded tumor cells [8].

In breast cancer, clinical utility has been demonstrated for the therascreen PIK3CA RGQ PCR kit, which detects PIK3CA mutations in a tissue biopsy and/or inctDNA obtained from a liquid biopsy in patients with an advanced or metastatic tumor [9]. The PIK3CA gene encodes for the p110α subunit of the phosphoinositide-3-kinase (PI3K) which promotes cell proliferation and survival by activation of the PI3K/AKT signaling pathway [10]. Mutations, mostly located in its catalytic domain, can lead to an activation of downstream pathways [11].

Further mutations that could act as targets for therapy in breast cancer are located in the ESRI, the AKTI, and the ERBB2 genes: the ESRI gene codes for the estrogen receptor α (ERα), a nuclear hormone receptor that is involved in the regulation of gene expression affecting cellular proliferation and differentiation [12]. Mutations in the ligand binding domain of ERα lead to a conformational change of the protein and to a ligand-independent ERα activation, mostly acquired in resistance to estrogen deprivation therapy such as aromatase inhibition [13,14]. AKT1 is a member of the serine-threonine kinase class and plays a key role in cellular processes, including growth, proliferation, survival, and angiogenesis. Certain AKTI mutations lead to hyperactivation of the mTOR pathway [15]. The receptor tyrosine-protein kinase ERBB2 (HER2/neu (HER2)) activates the RAS/MAPK, PI3K/AKT, and JAK/STAT signaling pathways to promote cell proliferation and survival. Mutations in the hotspot regions coding for the extracellular domain and the kinase domain lead to an activation of the protein and its downstream pathways [16].

In order to identify mutations for targeted therapy in breast cancer using CTCs, which have been enriched using the CellSearch system, we developed a multiplex PCR-based next generation sequencing (NGS)-panel. The CellSearch system has been approved by the Food and Drug Administration (FDA) for detection of CTCs in patients with metastatic breast, prostate, and colorectal cancer.

2. Materials and Methods

2.1. Patients

We analyzed CTCs from 13 metastatic breast cancer patients. Patients were selected from the Augusta study cohort collected at the Department of Obstetrics and Gynecology, Duesseldorf, Germany (approved by the Ethics Committee of the Medical Faculty of the Heinrich Heine University Düsseldorf; Ref-No: 3430). All patients gave their informed consent for the use of their blood samples for CTC analysis and translational research. Patients’ characteristics were anonymized by using sample identifiers. Clinical patient data are shown in Table 1.

2.2. Enrichment and Enumeration of CTCs

Enrichment and enumeration of CTCs was performed using the CellSearch Circulating Epithelial Cell Kit (Menarini, Florence, Italy) according to manufacturer’s instructions. Briefly, blood was collected into CellSave Preservative Tubes (Menarini) and was processed within 96 h. 7.5 mL blood was used for enumeration of CTCs. Enrichment is based on immunomagnetic ferrofluid conjugated with an epithelial cell adhesion molecule-directed antibody. Subsequent characterization of CTCs was performed using immunofluorescent staining directed against cytokeratins to identify CTCs, CD45 to exclude leucocytes and DAPI to confirm nucleo-morphological integrity.

2.3. CTC Isolation

Single CTCs were isolated from the CellSearch cartridge by micromanipulation with the CellCelector (ALS, Jena, Germany). Cells were deposited in PCR tubes to perform whole genome amplification (WGA) as described previously [17].
2.4. Whole-Genome Amplification

DNA of single isolated cells was amplified by WGA with the Ampli1 WGA Kit (Menarini) according to the manufacturer’s protocol. Afterwards DNA integrity was determined with the Ampli1 QC Kit (Menarini).

**Table 1. Patient characteristics.**

| Characteristics | Total | in % |
|-----------------|-------|------|
| Patients        | 13    | 100  |
| Age at blood draw |       |      |
| Mean            | 61.2  |      |
| Median          | 61    |      |
| Range           | 46–78 |      |
| Tumor size      |       |      |
| pT1             | 4     | 30.8 |
| pT2–4           | 8     | 61.5 |
| na              | 1     | 7.7  |
| Nodal status at time of diagnosis |       |      |
| 0               | 4     | 30.8 |
| 1–3             | 7     | 53.8 |
| na              | 2     | 15.4 |
| Metastasis status at time of diagnosis |       |      |
| 0               | 10    | 77.0 |
| 1               | 2     | 15.4 |
| na              | 1     | 7.7  |
| Histology       |       |      |
| NST             | 8     | 61.5 |
| Invasive-lobular | 5     | 38.5 |
| Grading         |       |      |
| 1–2             | 9     | 69.2 |
| 3               | 2     | 15.4 |
| na              | 2     | 23.1 |
| Subtype         |       |      |
| Luminal         | 11    | 84.6 |
| Triple negative | 2     | 15.4 |
| CTC count (per 7.5 mL blood) | Median | 94 |
| Range           | 6–15,340 | |

NST, invasive carcinoma of no special type; na, data not available; CTC, circulating tumor cell.

2.5. Multiplex PCR-Based Next Generation Sequencing

DNA fragments were amplified and barcoded in two steps using KAPA2G Fast Multiplex Mix (Merck, Darmstadt, Germany). In the first step, fragments coding for mutation hotspot regions were amplified with gene specific primers (Table 2) containing primer binding sites for universal Multiplicom MID Dx primers (Agilent technologies, Santa Clara, CA, USA) in a multiplex PCR. 1 µL WGA product and in total 0.5 µM gene specific primers were applied (concentrations of all primers are shown in Table S1). The concentration of each primer is shown in Table S1. In the second step, Multiplicom MID Dx primers were used to attach unique barcodes for sequencing to the PCR products. 0.5 µL of Multiplicom MID Dx primers and 0.5 µL of first round PCR product were used. The applied PCR protocols are listed in Table S2.

Final PCR products were purified using Agencourt AMPure XP beads (Beckmann Coulter, Brea, CA, USA) and quantified with the Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) using the Broad Range Quant-iT dsDNA Assay Kit (Thermo Fisher Scientific).

DNA libraries of 0.0143 pM per sample were sequenced on a MiSeq system (Illumina, San Diego, CA, USA) with 151 bp paired end reads.
FASTQ files were analyzed with the Galaxy web platform, using the public server at usegalaxy.org (last access for the Galaxy web platform: March 2020) [18]. Reads were aligned to the human reference genome (hg38) with BWA-MEM (Galaxy Version 0.7.17.1) [19]. Standard parameters were applied. Aligned sequences were screened for mutations using the IG Viewer (Version 2.3.25) [20]. Identified mutations were covered by >100× and had a variant allele frequency (VAF) >12.5%.

As controls, DNA from the reference cell lines mentioned below as well as a negative control was included in every run.

| Table 2. Primer overview. |
|---------------------------|
| **Forward Primer** | **Reverse Primer** |
| **PIK3CA Exon 5** | 5′ AAGACTCGGCACATCTCCAGC | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **PIK3CA Exon 10** | 5′ AAGACTCGCCAGACTCCAGGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **PIK3CA Exon 21** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **ESR1 Exon 5** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **ESR1 Exon 7** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **ESR1 Exon 8** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **AKT1 Exon 3** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **ERBB2 Exon 8** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **ERBB2 Exon 16** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |
| **ERBB2 Exon 19** | 5′ AAGACTCGGCACATCTCCAGG | 5′ GCGATCGTACCTCAGCCAGAGT |
| | ATTTCCACAGCTACACCA | GCTTCTCCTAACCAGCTCAGAGT |

### 2.6. Validation Experiments with Spiked Cells

For validation of the workflow, 200 cells of the cell lines SK-BR-3, T47-D, and MCF7 (ATCC, Manassas, United States; catalog numbers: SK-BR-3: HTB-30, T-47D: HTB133, and MCF7: HTB-22) as well as long term cultured CTCs were spiked into 7.5 mL healthy donor blood. For detachment from the culture flask, an enzyme-free cell dissociation buffer (Thermo Fisher Scientific) was used. The tumor cells were enriched using the CellSearch, isolated using the CellCelector and the genome was amplified with the Ampli1 WGA Kit similarly to CTCs.

The SK-BR-3, T47-D, and MCF7 cells were cultured in RPMI 1640 containing 10% fetal calf serum, 25 mmol/L HEPES and 1% Penicillin-Streptomycin (all Thermo Fisher Scientific). Cells were grown at 37 °C in a humidified atmosphere with 5% CO₂ and were authenticated via short tandem repeat analysis. CTCs were cultured as previously described in low attachment plates (Corning, New York, NY, USA) in RPMI 1640 medium supplemented with 1× B27 (Thermo Fisher Scientific), 20 ng/mL hEGF (Merck), 20 ng/mL FGF (Merck), and 1% Penicillin-Streptomycin in a humidified atmosphere with 5% CO₂ and 4% O₂ [21]. Cultured cells were regularly tested negative for Mycoplasma infection.

### 2.7. Statistical Analysis

Statistical analyses were performed using GraphPad Prism (Graphpad Software, San Diego, CA, USA). p-values < 0.05 were considered statistically significant.
3. Results

3.1. Development of the Assay

We aimed to develop a multiplex PCR-based NGS panel to identify mutations in CTCs relevant for targeted therapies in metastatic breast cancer, considering that the genomic DNA of single CTCs was amplified using an MseI restriction-based method. We included hotspot regions in the PIK3CA, ESR1, AKT1, and ERBB2 genes frequently mutated in breast cancers. In the PIK3CA gene, hotspot regions within the exons 5, 10, and 21 were covered. In the ESR1 gene, the hotspot regions in exons 5, 7, and 8 were analyzed. In the AKT1 gene, we investigated the hotspot regions in exon 3 and in the ERBB2 gene our assay covers the hotspot regions in exons 8, 18, 19, and 20. For each amplicon, a panel of primers was tested and the most specific primer combination was chosen for the multiplex PCR (Table 2, Figure S1). Primer concentrations in the first PCR were titrated resulting in an equal ratio for each fragment of 7.0% ± 1.4% to 10.2% ± 0.8% after sequencing (Figure S2). In total, we achieved an on target rate of 95.3% ± 0.9% of all reads.

Next, a group of CTCs of different quality determined by Ampli1 quality control was sequenced and the obtained coverage was compared. For cells with highest amplified DNA quality showing 4 bands in the quality control PCR a mean coverage of 10.2 ± 1.3 fragments per cell was observed (Figure 1). The coverage correlated with the quality determined with the quality control PCR. Cells displaying 3 or 4 bands in the quality control PCR had a significantly increased coverage compared to those with less than three bands (p < 0.0001 determined by two-tailed t-test). Thus, we focused on cells displaying at least 3 bands in the quality control PCR for further analysis to yield reliable results.

![Figure 1](image)

**Figure 1.** The number of covered fragments correlates with quality of WGA products. The p-value (p < 0.0001) was determined by two-tailed t-test. Error bars show standard deviation. For each group 10 to 30 cells were analyzed.

3.2. Validation of the Assay

To validate the assay, we performed spike in experiments using cells from four cell lines exhibiting different mutations. Those cells were processed applying the same workflow used later for clinical samples. As a negative control, cells from the Her2-enriched breast cancer cell line Sk-Br-3 harboring no mutations in the analyzed regions were analyzed. Cells from the luminal breast cancer cell lines T47-D and MCF7 were expected to show the PIK3CA mutations H1047R and E545K, respectively. Further, long term cultured CTCs derived from the DLA product of a metastatic luminal breast cancer patient harboring the ESR1 mutation E380Q and the AKT1 mutation E17K were analyzed. All investigated cells displayed the expected mutations demonstrating the reliability of our assay (Figure 2).
11 of those patients had a primary tumor of luminal subtype and two patients were diagnosed with well-described mutations located in the nucleotide triplets coding for the amino acid N345, E545, E17K, patient 2) or about 50% (e.g., AKT1 and AKT1 (Figure 3). The median CTC count was 94 per 7.5 mL blood. For our study, 1 to 15 CTCs per patient were analyzed.

In seven patients, mutations in the PIK3CA gene were identified. Five of those mutations are well-described mutations located in the nucleotide triplets coding for the amino acid N345, E545, and H1047, respectively. ESR1 mutations were detected in CTCs from two patients. One of those in the coding triplet for L536 is located in a well-known hotspot region. In CTCs from three patients, the AKT1 mutation E17K was found, and in CTCs from five patients we discovered mutations in the ERBB2 gene, including hotspot mutations in the nucleotide triplets coding for S310, L755, and V777 (Figure 3).

Mutations were detected in 16.7% (ERBB2 A775T, patient 4) to 100% (e.g., PIK3CA H1047R, patient 8) of the CTCs analyzed per patient. In two cases, mutations were detected in two genes (AKT1 and ERBB2, patient 6; PIK3CA and ERBB2, patient 8) per patient, in 1 patient we found mutations in three genes (PIK3CA, ESR1, and AKT1, patient 3). Those mutations either occurred in different CTCs (e.g., AKT1 and PIK3CA mutations in CTCs from patient 3) or together in one cell (e.g., PIK3CA and ERBB2 mutations in patient 8). One CTC from patient 3 harbored two activating mutations within the same gene (PIK3CA N345K and H1047R). Most mutations were detected with frequencies of 100% (e.g., AKT1 E17K, patient 2) or about 50% (e.g., PIK3CA H1047R, patient 8).

### Table 1

| Cell line | PIK3CA | ESR1 | AKT1 |
|-----------|--------|------|------|
| ID        | E545K  | E1047R | E380Q | E17K |
| Sk-BR-3   |        |       |      |
| 1         |        |       |      |
| 2         |        |       |      |
| 3         |        |       |      |
| 4         |        |       |      |
| 5         |        |       |      |
| 6         |        |       |      |
| T47-D     |        |       |      |
| 1         |        | 21%   |      |
| 2         |        | 24%   |      |
| 3         |        | 100%  |      |
| MCF-7     |        |       |      |
| 1         | 49%    |       |      |
| 2         | 58%    |       |      |
| 3         | 75%    |       |      |
| 4         | 57%    |       |      |
| 5         | 41%    |       |      |
| CTC (LTC) |        |       |      |
| 1         | 100%   | 50%   |
| 2         | 100%   | 100%  |
| 3         | 100%   | 41%   |

**Figure 2.** Sequencing data of cells from reference cell lines. Displayed values show the variant allele frequency. Empty boxes indicate that no mutation was detected. LTC, long term cultured.

### 3.3. Analysis of CTCs from Metastatic Breast Cancer Patients to Identify Targeted Therapies

After validation with cell line cells we analyzed CTCs from 13 metastatic breast cancer patients. 11 of those patients had a primary tumor of luminal subtype and two patients were diagnosed with triple negative breast cancer. CellSearch analyses determined 6 to 15,340 CTCs per 7.5 mL blood. The median CTC count was 94 per 7.5 mL blood. For our study, 1 to 15 CTCs per patient were analyzed.

In seven patients, mutations in the PIK3CA gene were identified. Five of those mutations are well-described mutations located in the nucleotide triplets coding for the amino acid N345, E545, and H1047, respectively. ESR1 mutations were detected in CTCs from two patients. One of those in the coding triplet for L536 is located in a well-known hotspot region. In CTCs from three patients, the AKT1 mutation E17K was found, and in CTCs from five patients we discovered mutations in the ERBB2 gene, including hotspot mutations in the nucleotide triplets coding for S310, L755, and V777 (Figure 3).
Figure 3. Sequencing data from CTCs. Displayed values show the variant allele frequency. Empty boxes indicate that no mutation was detected.
4. Discussion

Mutations detected in cancer can help to choose an appropriate targeted therapy. In the advanced disease, analysis of a liquid biopsy can facilitate to identify such druggable targets. Various studies reported suitable tools for the analysis of single CTCs’ WGA-products, either by investigation of single genomic positions by e.g., Sanger sequencing [22,23] or by sequencing multiple genomic positions by, e.g., NGS panels [24,25]. However, most available assays are either cost intensive, not adapted to single cell whole genome amplified DNA, or cover only single or not all relevant genomic positions for therapy selection in breast cancer. Here, we developed and provided the protocol for a multiplex PCR-based, Ampli1 WGA-adapted NGS panel that covers mutation hotspots in the PIK3CA, the ESR1, the AKT1, and the ERBB2 genes that are most relevant for a liquid biopsy-based targeted therapy in breast cancer.

The assay was validated with spiked cell line cells and finally applied to CTCs from metastatic breast cancer patients. Mutations that provide the basis for potential targeted therapy were detected in 10 out of 13 patients. Although one CTC from patient 4 was found to harbor the ERBB2 A775T mutation, it was not considered as clinically targetable since this mutation has not been characterized in breast cancer, yet. For the treatment of hormone receptor-positive, HER2-negative advanced breast cancers harboring PIK3CA variants such as N345K, E545K, H1047L, or H1047R, alpelisib plus fulvestrant is indicated [26]. Furthermore, HER2-positive tumors of patients with this variant exhibited resistance to trastuzumab [27]. The detected ESR1 L536P mutation leads to a conformational change of the protein and to a ligand-independent ERα activation, thereby conferring resistance to aromatase inhibition [13]. However, treatment with second-generation selective ERα degraders such as fulvestrant is recommended [28]. The AKT1 E17K mutation hyperactivates the mTOR pathway that could be targeted by mTOR inhibitors, such as everolimus, or AKT-inhibitors, such as ipatasertib and capivasertib [29,30]. Mutations such as S310F, L755S, or V777L in the ERBB2 gene offer to be treated with the tyrosine kinase inhibitor neratinib [16].

The frequency of PIK3CA and AKT1 mutations in our patient cohort exceeded the frequencies published in literature. AKT1 E17K mutation frequencies between 1.4% and 8.2% have been described in breast cancer tissue [31] and mutations of the PIK3CA gene are found in 25%–40% of all breast cancers [32,33]. One reason for that is that such mutations can be acquired during the metastasis process leading to a discrepancy of the mutation status of the primary tumor and a liquid biopsy [34]. Furthermore, mutations in the PIK3CA and the AKT1 gene lead to an increased proliferation of the tumor combined with reduced apoptosis [10,15] and might thereby cause a higher probability of CTCs detected in general and of CTCs with a high genome integrity in particular.

Most of the mutations we detected were located in well-described hotspot regions. Some mutations, however, are novel and have not been reported yet, such as the PIK3CA M318T, ERBB2 L313P, or the ERBB2 A775T mutations. These mutations were only detected in single WGA products and due to prior WGA, a false positive result cannot be totally excluded. To further investigate these mutations, tools to predict the effect on the protein structure have been applied [35–37]. Although they are not fully consistent, the results indicate that these mutations might affect the function of the protein (Table S3).

Heterogeneity was observed within CTCs from almost all patients. Such heterogeneity indicates that different subclones exist within the tumor and that the patient might therefore benefit from the combination of treatments targeting different proteins. However, it cannot be excluded that the observed assumed heterogeneity may at least in part be caused by false negativity due to allelic dropout during WGA. Thus, the absence of mutations does not necessarily mean that these mutations were not present in the initial cells. One example for allelic dropout is the T47-D reference cell 3: in this cell, only the mutated allele was amplified during WGA. This effect of allelic dropout is limiting all approaches for the analysis of DNA from single cells. The probability of allelic dropout increases with reduced DNA integrity. To minimize it, we focused on the analysis of WGA products that showed at least three bands in the quality control PCR.
Most studies on the clinical utility on mutations have been performed on ctDNA. However, the clinical utility of ctDNA and CTCs has not been compared so far and the analysis of CTCs and ctDNA might be complementary [34].

Altogether, we have developed a time and cost effective multiplex PCR-based assay for the analysis on a MiSeq system. Our assay covers the most relevant positions indicative for targeted therapies in breast cancer and can thereby improve therapy decision and help to improve the treatment of cancer patients eventually.

Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3417/10/10/3364/s1, Table S1: Primer concentrations used in first PCR, Table S2: PCR protocols, Figure S1: Validation of first PCR, Figure S2: Distribution of reads to the analyzed fragments, Table S3: Prediction of effect of detected amino acid substitutions.

Author Contributions: A.F., T.F., and H.N. conceived the project and provided project leadership. A.F. and H.N. wrote the manuscript. M.R. and L.Y. contributed to single cell isolation. B.J. and N.K. contributed to sample collection. E.H. and D.N. contributed to data analysis. All authors read and approved the final manuscript.

Funding: AF was supported by the Duesseldorf School of Oncology (funded by the Comprehensive Cancer Centre Duesseldorf/Deutsche Krebshilfe and the Medical Faculty of the Heinrich Heine University Duesseldorf).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Perakis, S.; Speicher, M.R. Emerging concepts in liquid biopsies. BMC Med. 2017, 15, 75. [CrossRef] [PubMed]
2. Turajlic, S.; Sottoriva, A.; Graham, T.; Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 2019, 20, 404–416. [CrossRef] [PubMed]
3. Palmirotta, R.; Lovero, D.; Cafforio, P.; Felici, C.; Mannavola, F.; Pellé, E.; Quaresmini, D.; Tucci, M. Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Ther. Adv. Med. Oncol. 2018, 10, 175835918794630. [CrossRef] [PubMed]
4. Pantel, K.; Alix-Panabières, C. Circulating tumour cells in cancer patients: Challenges and perspectives. Trends Mol. Med. 2010, 16, 398–406. [CrossRef]
5. Barradas, A.M.C.; Terstappen, L.W.M.M. Towards the biological understanding of CTC: Capture technologies, definitions and potential to create metastasis. Cancers 2013, 5, 1619–1642. [CrossRef]
6. Yu, M.; Stott, S.; Toner, M.; Maheswaran, S.; Haber, D.A. Circulating tumor cells: Approaches to isolation and characterization. J. Cell Biol. 2011, 192, 373–382. [CrossRef]
7. Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.J.; Uhr, J.W.; Terstappen, L.W.M.M. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients with Nonmalignant Diseases. Clin. Cancer Res. 2005, 10, 6897–6904. [CrossRef]
8. Wan, J.C.M.; Massie, C.; Garcia-Corbacho, J.; Mouliere, F.; Brenton, J.D.; Caldas, C.; Pacey, S.; Baird, R.; Rosenfeld, N. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat. Rev. Cancer 2017, 17, 223–238. [CrossRef]
9. FDA Oncology Update. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684051/ (accessed on 1 March 2020).
10. Janku, F.; Yap, T.A.; Meric-Bernstam, F. Targeting the PI3K pathway in cancer: Are we making headway? Nat. Rev. Clin. Oncol. 2018, 15, 273–291. [CrossRef]
11. Zhao, L.; Vogt, P.K. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA 2008, 105, 2652–2657. [CrossRef]
12. Arpino, G.; Wiechmann, L.; Osborne, C.K.; Schöff, R. Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance. Endocr. Rev. 2008, 29, 217–233. [CrossRef] [PubMed]
13. Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R.A.; Will, M.; Gala, K.; Fanning, S.; King, T.a.; Hudis, C.; et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45, 1439–1445. [CrossRef] [PubMed]
14. Franken, A.; Honisch, E.; Reinhardt, F.; Meier-Stielen, F.; Yang, L.; Jaschinski, S.; Esposito, I.; Alberter, B.; Polzer, B.; Huebner, H.; et al. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. *J. Mol. Diagn.* 2019, **22**, 111–121. [CrossRef]

15. Carpten, J.D.; Faber, A.L.; Horn, C.; Donoho, G.P.; Briggs, S.L.; Robbins, C.M.; Hostetter, G.; Boguslawski, S.; Moses, T.Y.; Savage, S.; et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 2007, **448**, 439–444. [CrossRef] [PubMed]

16. Bose, R.; Kavuri, S.M.; Searleman, A.C.; Shen, W.; Shen, D.; Koboldt, D.C.; Monsey, J.; Goel, N.; Aronson, A.B.; Li, S.; et al. Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. *Cancer Discov.* 2013, **3**, 224–237. [CrossRef] [PubMed]

17. Neumann, M.H.D.; Schneck, H.; Decker, Y.; Schömer, S.; Franken, A.; Endris, V.; Pfarr, N.; Weichert, W.; Niederacher, D.; Fehm, T.; et al. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™. *Biotechnol. Prog.* 2017, **33**, 125–132. [CrossRef]

18. Afgan, E.; Baker, D.; van de Beek, M.; Blankenberg, D.; Bouvier, D.; Čech, M.; Chilton, J.; Clements, D.; Coraor, N.; Eberhard, C.; et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. *Nucleic Acids Res.* 2016, **44**, W3–W10. [CrossRef]

19. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv* 2013, arXiv:1303.3997.

20. Thorvaldsdóttir, H.; Robinson, J.T.; Mesirov, J.P. Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. *Brief. Bioinform.* 2013, **14**, 178–192. [CrossRef]

21. Franken, A.; Driemel, C.; Behrens, B.; Meier-stielen, F.; Endris, V.; Stenzinger, A.; Niederacher, D.; Fischer, J.C.; Stoecklein, N.H.; Ruckhaebler, E.; et al. Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. *Clin. Chem.* 2019, **65**, 549–558. [CrossRef]

22. Lampignano, R.; Yang, L.; Neumann, M.H.D.; Franken, A.; Fehm, T.; Niederacher, D.; Neubauer, H. A novel workflow to enrich and isolate patient-matched EpCAMhigh and EpCAMlow circulating tumor cells. *Clin. Cancer Res.* 2017, **23**, 88–96. [CrossRef] [PubMed]

23. Paolillo, C.; Mu, Z.; Rossi, G.; Schiewer, M.J.; Nguyen, T.; Austin, L.; Capoluongo, E.; Knudsen, K.; Cristofanilli, M.; Fortina, P. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells. *Clin. Cancer Res.* 2017, **23**, 6086–6093. [CrossRef] [PubMed]

24. Shaw, J.A.; Guttery, D.S.; Hills, A.; Fernandez-Garcia, D.; Page, K.; Rosales, B.M.; Goddard, K.S.; Hastings, R.K.; Luo, J.; Ogle, O.; et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. *Clin. Cancer Res.* 2017, **23**, 88–96. [CrossRef] [PubMed]

25. Onidani, K.; Shoji, H.; Kazikazi, T.; Yoshimoto, S.; Okaya, S.; Miura, N.; Sekikawa, S.; Furuta, K.; Lim, C.T.; Shibahara, T.; et al. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA. *Cancer Sci.* 2019, **110**, 2590–2599. [CrossRef] [PubMed]

26. André, F.; Ciruelos, E.; Rubovszky, G.; Campone, M.; Loibl, S.; Rugo, H.S.; Ivata, H.; Conte, P.; Mayer, I.A.; Kaufman, B.; et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. *N. Engl. J. Med.* 2019, **380**, 1929–1940. [CrossRef]

27. Chandarlapaty, S.; Sakr, R.A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; et al. Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. *Clin. Cancer Res.* 2012, **18**, 6784–6791. [CrossRef]

28. Fribbens, C.; O’Leary, B.; Kilburn, L.; Hrebien, S.; Garcia-Murillas, I.; Beaney, M.; Cristofanilli, M.; Andre, F.; Loi, S.; Loibl, S.; et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. *J. Clin. Oncol.* 2016, **34**, 2961–2968. [CrossRef]

29. Hyman, D.M.; Smyth, L.M.; Donoghue, M.T.A.; Westin, S.N.; Bedard, P.L.; Emma, J.; Bando, H.; El-khouery, A.B.; Mita, A.; Schellens, J.H.M.; et al. AKT Inhibition in Solid Tumors with AKT1 Mutations. *J. Clin. Oncol.* 2019, **37**, 2251–2262. [CrossRef]

30. Zardavas, D.; Fumagalli, D.; Loi, S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: A breakthrough in the management of luminal (ER+/HER2−) breast cancers? *Curr. Opin. Oncol.* 2012, **24**, 623–634. [CrossRef]
31. Troxell, M.L. PIK3CA/AKT1 Mutations in Breast Carcinoma: A Comprehensive Review of Experimental and Clinical Studies. J. Clin. Exp. Pathol. 2012. [CrossRef]
32. Mukohara, T. Pi3k mutations in breast cancer: Prognostic and therapeutic implications. Breast Cancer Targets Ther. 2015, 7, 111–123. [CrossRef]
33. Samuels, Y.; Waldman, T. Oncogenic mutations of PIK3CA in human cancers. Curr. Top. Microbiol. Immunol. 2010, 346, 21–41.
34. Tzanikou, E.; Markou, A.; Politaki, E.; Koutsepalou, A.; Pyrri, A.; Mavroudis, D.; Georgoulas, V.; Lianidou, E. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: A direct comparison study. Mol. Oncol. 2019, 13, 2515–2530. [CrossRef] [PubMed]
35. Adzhubei, I.; Jordan, D.M.; Sunyaev, S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 2013, 76, 7.20.1–7.20.41. [CrossRef] [PubMed]
36. Tavtigian, S.V.; Deffenbaugh, A.M.; Yin, L.; Judkins, T.; Scholl, T.; Samollow, P.B.; De Silva, D.; Zharkikh, A.; Thomas, A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J. Med. Genet. 2006, 43, 295–305. [CrossRef] [PubMed]
37. Choi, Y.; Chan, A.P. PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 2015, 31, 2745–2747. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).